[{"id":"86dcbaa4-a0f7-4722-b301-afe751349fdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT07479485","created_at":"2026-03-28T01:39:14.150Z","updated_at":"2026-03-28T01:39:14.150Z","phase":"Phase 1/2","brief_title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","source_id_and_acronym":"NCT07479485","lead_sponsor":"Lepu Biopharma Co., Ltd.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Puyouheng (pucotenlimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2026-03-18"},{"id":"37515089-1ee4-4286-99b0-7bb0298fc653","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472153","created_at":"2026-03-28T01:41:57.745Z","updated_at":"2026-03-28T01:41:57.745Z","phase":"Phase 2/3","brief_title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","source_id_and_acronym":"NCT07472153","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"8fac6d48-bf25-4ede-b0bd-19869334e342","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472140","created_at":"2026-03-28T01:41:57.184Z","updated_at":"2026-03-28T01:41:57.184Z","phase":"Phase 2/3","brief_title":"PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT07472140","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"78368562-545f-4c40-b6de-f2d2cbfd2a71","acronym":"","url":"https://clinicaltrials.gov/study/NCT07183865","created_at":"2025-09-27T08:40:54.392Z","updated_at":"2025-09-27T08:40:54.392Z","phase":"Phase 2","brief_title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","source_id_and_acronym":"NCT07183865","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/09/2025","start_date":" 03/09/2025","primary_txt":" Primary completion: 03/09/2030","primary_completion_date":" 03/09/2030","study_txt":" Completion: 03/09/2030","study_completion_date":" 03/09/2030","last_update_posted":"2025-09-19"},{"id":"55b1a0de-6575-4213-92f4-3ad23c6cc089","acronym":"","url":"https://clinicaltrials.gov/study/NCT07150403","created_at":"2025-09-06T13:44:19.461Z","updated_at":"2025-09-06T13:44:19.461Z","phase":"Phase 2","brief_title":"A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT07150403","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2025-09-02"},{"id":"5896371c-1ef5-48dc-96cb-56888e31ddde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07150247","created_at":"2025-09-06T13:44:15.174Z","updated_at":"2025-09-06T13:44:15.174Z","phase":"Phase 2","brief_title":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT07150247","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-09-02"},{"id":"dd30cd49-1fd8-43e7-b783-449eccebfd62","acronym":"","url":"https://clinicaltrials.gov/study/NCT07070713","created_at":"2025-07-19T14:10:13.961Z","updated_at":"2025-07-19T14:10:13.961Z","phase":"Phase 2","brief_title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","source_id_and_acronym":"NCT07070713","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/30/2025","start_date":" 07/30/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 08/30/2028","study_completion_date":" 08/30/2028","last_update_posted":"2025-07-17"},{"id":"e87af69a-d323-4381-8103-c49ab9c91458","acronym":"","url":"https://clinicaltrials.gov/study/NCT06934538","created_at":"2025-07-12T13:49:40.870Z","updated_at":"2025-07-12T13:49:40.870Z","phase":"Phase 1/2","brief_title":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06934538","lead_sponsor":"Brenus Pharma","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • cyclophosphamide • oxaliplatin • STC-1010"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/17/2025","start_date":" 06/17/2025","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-07-11"},{"id":"e43e3d0d-a928-4113-b0cb-1cb1cbe5fa52","acronym":"","url":"https://clinicaltrials.gov/study/NCT07044908","created_at":"2025-07-05T14:01:51.038Z","updated_at":"2025-07-05T14:01:51.038Z","phase":"Phase 1/2","brief_title":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","source_id_and_acronym":"NCT07044908","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-07-01"},{"id":"08660c39-94ce-46e6-891f-cb32c681d233","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012954","created_at":"2025-06-14T13:57:24.505Z","updated_at":"2025-06-14T13:57:24.505Z","phase":"Phase 1/2","brief_title":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","source_id_and_acronym":"NCT07012954","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-06-10"},{"id":"2304e211-cb24-49e4-804c-c1f372c07411","acronym":"ARTEMIDE-HCC01","url":"https://clinicaltrials.gov/study/NCT06921785","created_at":"2025-06-07T14:44:45.235Z","updated_at":"2025-06-07T14:44:45.235Z","phase":"Phase 3","brief_title":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","source_id_and_acronym":"NCT06921785 - ARTEMIDE-HCC01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imjudo (tremelimumab-actl) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 1220","initiation":"Initiation: 05/06/2025","start_date":" 05/06/2025","primary_txt":" Primary completion: 03/16/2029","primary_completion_date":" 03/16/2029","study_txt":" Completion: 03/15/2030","study_completion_date":" 03/15/2030","last_update_posted":"2025-05-31"},{"id":"a81aca55-51bd-4c9d-98b4-44d67b97640e","acronym":"KANDLELIT-012","url":"https://clinicaltrials.gov/study/NCT06997497","created_at":"2025-06-07T14:50:31.299Z","updated_at":"2025-06-07T14:50:31.299Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","source_id_and_acronym":"NCT06997497 - KANDLELIT-012","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • calderasib (MK-1084) • levoleucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 477","initiation":"Initiation: 07/17/2025","start_date":" 07/17/2025","primary_txt":" Primary completion: 08/27/2029","primary_completion_date":" 08/27/2029","study_txt":" Completion: 06/29/2031","study_completion_date":" 06/29/2031","last_update_posted":"2025-05-30"},{"id":"c8aaef7c-6714-47f7-9635-9d89ae988ee2","acronym":"LIBRA","url":"https://clinicaltrials.gov/study/NCT06982924","created_at":"2025-09-07T01:40:22.807Z","updated_at":"2025-09-07T01:40:22.807Z","phase":"Phase 2","brief_title":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","source_id_and_acronym":"NCT06982924 - LIBRA","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • limertinib (ASK120067)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-05-21"},{"id":"5dee5c4e-4cac-4602-831a-304102b4edeb","acronym":"CRIT","url":"https://clinicaltrials.gov/study/NCT06908031","created_at":"2025-09-07T01:12:45.769Z","updated_at":"2025-09-07T01:12:45.769Z","phase":"Phase 2","brief_title":"SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer","source_id_and_acronym":"NCT06908031 - CRIT","lead_sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 04/02/2025","start_date":" 04/02/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-05-14"},{"id":"12474215-8ccb-4758-b817-b0ea028361d5","acronym":"x-МАР","url":"https://clinicaltrials.gov/study/NCT06949982","created_at":"2025-07-19T13:21:59.299Z","updated_at":"2025-07-19T13:21:59.299Z","phase":"Phase 2","brief_title":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes","source_id_and_acronym":"NCT06949982 - x-МАР","lead_sponsor":"Sergey Orlov, MD","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • methotrexate • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/17/2025","start_date":" 03/17/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-05-04"},{"id":"ddb28914-edb2-4733-8bbd-06431d3d7e9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856837","created_at":"2025-09-07T01:48:45.276Z","updated_at":"2025-09-07T01:48:45.276Z","phase":"Phase 2","brief_title":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","source_id_and_acronym":"NCT06856837","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-03-04"},{"id":"0275af4d-adea-470c-80d3-2b61aa1c8803","acronym":"","url":"https://clinicaltrials.gov/study/NCT01950390","created_at":"2021-01-18T08:50:38.167Z","updated_at":"2025-02-25T12:26:04.772Z","phase":"Phase 2","brief_title":"Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01950390","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • CS1002 (ipilimumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 01/24/2014","start_date":" 01/24/2014","primary_txt":" Primary completion: 10/06/2021","primary_completion_date":" 10/06/2021","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"056fe673-cdf1-43ac-850b-4889f543f569","acronym":"","url":"https://clinicaltrials.gov/study/NCT03169790","created_at":"2021-01-18T15:37:43.674Z","updated_at":"2025-02-25T12:26:42.620Z","phase":"Phase 1/2","brief_title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","source_id_and_acronym":"NCT03169790","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 12/23/2021","study_completion_date":" 12/23/2021","last_update_posted":"2025-02-24"},{"id":"6a7737ea-7363-4409-b641-c11409e515ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181060","created_at":"2021-01-18T20:23:16.793Z","updated_at":"2025-02-25T12:37:29.255Z","phase":"Phase 3","brief_title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","source_id_and_acronym":"NCT04181060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-24"},{"id":"c79faf97-f729-4398-957b-5d83e409d779","acronym":"COMMIT","url":"https://clinicaltrials.gov/study/NCT02997228","created_at":"2021-01-18T14:45:08.921Z","updated_at":"2025-02-25T12:26:35.429Z","phase":"Phase 3","brief_title":"Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study","source_id_and_acronym":"NCT02997228 - COMMIT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR","tags":["PD-L1 • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/19/2018","start_date":" 01/19/2018","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-24"},{"id":"e6b99f28-6a26-4cf9-aa0c-52200cf1061c","acronym":"ECOG-ACRIN EA3202","url":"https://clinicaltrials.gov/study/NCT05063552","created_at":"2021-10-01T12:54:14.078Z","updated_at":"2025-02-25T12:28:23.682Z","phase":"Phase 2/3","brief_title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","source_id_and_acronym":"NCT05063552 - ECOG-ACRIN EA3202","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/15/2027","primary_completion_date":" 12/15/2027","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2025-02-24"},{"id":"f49513f4-2324-4f1a-bfa6-fcc569055fc2","acronym":"STAR-T","url":"https://clinicaltrials.gov/study/NCT05839951","created_at":"2023-05-03T15:04:35.012Z","updated_at":"2025-02-25T12:29:31.860Z","phase":"","brief_title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","source_id_and_acronym":"NCT05839951 - STAR-T","lead_sponsor":"Bayer","biomarkers":" KRAS • MSI","pipe":"","alterations":" ","tags":["KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 04/24/2023","start_date":" 04/24/2023","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-24"},{"id":"b6ca3d93-c186-4751-9a4a-5de77d5b1a3b","acronym":"MOUNTAINEER-03","url":"https://clinicaltrials.gov/study/NCT05253651","created_at":"2022-02-24T14:52:50.182Z","updated_at":"2025-02-25T13:36:05.619Z","phase":"Phase 3","brief_title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05253651 - MOUNTAINEER-03","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" RAS wild-type","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/24/2022","start_date":" 10/24/2022","primary_txt":" Primary completion: 04/03/2026","primary_completion_date":" 04/03/2026","study_txt":" Completion: 07/27/2029","study_completion_date":" 07/27/2029","last_update_posted":"2025-02-21"},{"id":"9477387b-6d4d-44dc-94ca-1342835e5367","acronym":"BREAKWATER","url":"https://clinicaltrials.gov/study/NCT04607421","created_at":"2021-01-19T20:31:44.383Z","updated_at":"2025-02-25T13:53:29.320Z","phase":"Phase 3","brief_title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04607421 - BREAKWATER","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Braftovi (encorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Zirabev (bevacizumab-bvzr) • Khapzory (levoleucovorin) • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 823","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 01/06/2025","primary_completion_date":" 01/06/2025","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-20"}]